Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis.
설문조사
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
649 patients, with a median age of 60 years, 51% male, 60% White, 10% Black, and 20% Hispanic.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Patients with undergoing HCC surveillance prioritize surveillance test sensitivity; however, results vary by race, ethnicity, and SES. Improving access by reducing financial and logistical barriers through shared-decision-making may enhance surveillance, particularly when modalities present with similar effectiveness.
OpenAlex 토픽 ·
Economic and Environmental Valuation
Organ Transplantation Techniques and Outcomes
Patient Satisfaction in Healthcare
[BACKGROUND] Several emerging modalities are available for hepatocellular carcinoma (HCC) surveillance; however, patient preferences for surveillance tests - particularly across key subgroups such as
- p-value p<0.001
- p-value p=0.001
- 95% CI 40.6-45.1
APA
Karissa D. Kao, Jonathan P. Troost, et al. (2026). Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis.. The American journal of gastroenterology. https://doi.org/10.14309/ajg.0000000000004023
MLA
Karissa D. Kao, et al.. "Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis.." The American journal of gastroenterology, 2026.
PMID
41979434
Abstract
[BACKGROUND] Several emerging modalities are available for hepatocellular carcinoma (HCC) surveillance; however, patient preferences for surveillance tests - particularly across key subgroups such as race/ethnicity, income, and education level - are poorly characterized.
[METHODS] We conducted a choice-based conjoint survey among patients with cirrhosis and chronic hepatitis B undergoing HCC surveillance (from 2022-2024) at seven centers in the US. Participants were presented with 15 scenarios, where they chose between surveillance modalities based on test attributes.
[RESULTS] We included 649 patients, with a median age of 60 years, 51% male, 60% White, 10% Black, and 20% Hispanic. The cohort reflected substantial socioeconomic variation including 12% with Medicaid and 38% with Medicare. The highest priority attribute was surveillance benefits (42.9%; 95% CI: 40.6-45.1%), followed by financial harms (19.4%; 95% CI: 18.1-20.7%). Patients placed less priority on test logistics (12.3%; 95% CI: 11.5-13.2%), test location (9.2%; 95% CI: 8.5-10.0%), test duration (8.3%; 95% CI: 7.8-8.7%), and physical harms (7.9%; 95% CI: 7.2-8.6%). In subgroup analyses, Black participants placed significantly lower importance on surveillance benefits and higher importance on financial harms (p<0.001) and test duration (p=0.001) compared to White participants. Hispanic participants also prioritized financial harms more than non-Hispanic participants (p<0.001), a pattern consistent with cost-related concerns seen across other lower socioeconomic status (SES) subgroups. Lower SES individuals with below a high school education (p=0.01), Medicaid insurance (p=0.001), and income below $25,000 (p<0.001) assigned greater importance to financial harms and less to surveillance benefits.
[CONCLUSIONS] Patients with undergoing HCC surveillance prioritize surveillance test sensitivity; however, results vary by race, ethnicity, and SES. Improving access by reducing financial and logistical barriers through shared-decision-making may enhance surveillance, particularly when modalities present with similar effectiveness.
[METHODS] We conducted a choice-based conjoint survey among patients with cirrhosis and chronic hepatitis B undergoing HCC surveillance (from 2022-2024) at seven centers in the US. Participants were presented with 15 scenarios, where they chose between surveillance modalities based on test attributes.
[RESULTS] We included 649 patients, with a median age of 60 years, 51% male, 60% White, 10% Black, and 20% Hispanic. The cohort reflected substantial socioeconomic variation including 12% with Medicaid and 38% with Medicare. The highest priority attribute was surveillance benefits (42.9%; 95% CI: 40.6-45.1%), followed by financial harms (19.4%; 95% CI: 18.1-20.7%). Patients placed less priority on test logistics (12.3%; 95% CI: 11.5-13.2%), test location (9.2%; 95% CI: 8.5-10.0%), test duration (8.3%; 95% CI: 7.8-8.7%), and physical harms (7.9%; 95% CI: 7.2-8.6%). In subgroup analyses, Black participants placed significantly lower importance on surveillance benefits and higher importance on financial harms (p<0.001) and test duration (p=0.001) compared to White participants. Hispanic participants also prioritized financial harms more than non-Hispanic participants (p<0.001), a pattern consistent with cost-related concerns seen across other lower socioeconomic status (SES) subgroups. Lower SES individuals with below a high school education (p=0.01), Medicaid insurance (p=0.001), and income below $25,000 (p<0.001) assigned greater importance to financial harms and less to surveillance benefits.
[CONCLUSIONS] Patients with undergoing HCC surveillance prioritize surveillance test sensitivity; however, results vary by race, ethnicity, and SES. Improving access by reducing financial and logistical barriers through shared-decision-making may enhance surveillance, particularly when modalities present with similar effectiveness.